Hidden Hearing Respond to Hearing Loss Drug Trial Launch

Share Article

Leaders in private hearing healthcare, Hidden Hearing, has responded to news that pharmaceutical company Autifony Therapeutics has began trials on a hearing loss drug.

News Image
AUT00063 is designed to work as a novel agent which targets auditory processing in the brain and deficiencies which are thought to play a key role in hearing problems in the elderly as well as tinnitus.

A UK biotech has launched a Phase 1 trial of its experimental drug to tackle hearing disorders and tinnitus – reports Pharma Times Online.

Following financial backing from Pfizer Venture Investments, International Biotechnology Trust, SV Life Sciences, Imperial Innovations plc and UCL Business plc – the project now has a total of £15.75 million funding.

Autifony Therapeutics, a GlaxoSmithKline spin-off group, will assess the safety and dosing of AUT00063 on around 60 people for the treatment of hearing loss and tinnitus.

AUT00063 is designed to work as a novel agent which targets auditory processing in the brain and deficiencies which are thought to play a key role in hearing problems in the elderly as well as tinnitus.

The trial, which is taking place in the UK is expected to complete by the first quarter of next year.

A spokesperson from Hidden Hearing said:

“There has been a lot of research into drug solutions for hearing loss, but this drug trial demonstrates one of the first possibilities of an effective treatment for hearing loss. It will be interesting to see what results the trial will reveal and what this could be for hearing loss and tinnitus treatment in future.”

With more than 40 years’ experience in treating hearing loss, Hidden Hearing is entrusted with the care of more than 100,000 people each year. The firm has 84 hearing centres across the UK, all catering for a range of needs and budgets. Specialising in hearing tests and hearing aids, the company also offer a variety of hearing aid accessories and in 2005, became the first dedicated hearing retailer to be recognised as an Investor in People.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Vicky Moore
Visit website